The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist. - Wikidata - awgldk - TriplyDB

The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.

The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.

http://www.wikidata.org/entity/Q34726309

about

Liraglutide and obesity: a review of the data so far.Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?

P2860

Q30924982-C9890863-1561-4A0F-BBDE-4AFEB3C9D373 Q37737468-A6DE2F2E-AEB4-44D8-9AC5-1087834F4CEF Q37737470-79625F4D-7057-41B9-983C-DC9850B349C6 Q38616170-97C308D9-F474-4EE3-9483-EBE574F99417 Q38765656-5DD513C8-DBB8-4686-84E9-5B7EC869928B Q39157526-2AA1CF90-D62B-4C83-8630-9761AE267395

P2860

The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.

http://www.wikidata.org/entity/Q34726309

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The clinical development progr ...... ke Peptide-1 receptor agonist.

@ast

The clinical development progr ...... ke Peptide-1 receptor agonist.

@en

The clinical development progr ...... ke Peptide-1 receptor agonist.

@nl

type

label

The clinical development progr ...... ke Peptide-1 receptor agonist.

@ast

The clinical development progr ...... ke Peptide-1 receptor agonist.

@en

The clinical development progr ...... ke Peptide-1 receptor agonist.

@nl

prefLabel

The clinical development progr ...... ke Peptide-1 receptor agonist.

@ast

The clinical development progr ...... ke Peptide-1 receptor agonist.

@en

The clinical development progr ...... ke Peptide-1 receptor agonist.

@nl

P1433

Q34726309-56547498-9CBD-4146-A764-089D9DA78DAE

P1476

Q34726309-54712666-AE2F-4FD5-807A-39ADF0BA7431

P2093

Q34726309-3022E920-E9FF-4B5D-9F6E-A0204344F3C0

P2860

Q34726309-02C0E042-A7FD-4571-B739-D035E67C7E47

Q34726309-135450E3-69A7-4955-AD3A-9DDA465AA8FF

Q34726309-21F361C6-FE73-4265-8E55-92C3EDBC961A

Q34726309-2E6E041B-22E1-4AA3-9414-FB5D00CACE9B

Q34726309-30892A25-0AD4-4736-BDFF-7699552DFFE1

Q34726309-375FDD7E-7789-47FA-8066-BF3A6791B85D

Q34726309-38AF4145-C47C-4CC4-AC14-C9A73D978852

Q34726309-498CC3E0-B036-4709-B35A-A17EF2C5D79C

Q34726309-4BFC4ECD-0039-46A7-AFAC-FFDB63686FD6

Q34726309-5DD9477E-C0D2-4794-A801-226A2191367D

P2888

Q34726309-79D0AC01-4F24-44A4-95B7-B8EFA3144A46

P304

Q34726309-7076FD2E-6639-45A1-B1CF-0D48AB239CBE

P31

Q34726309-E7A2A7E8-C70A-4CD3-811A-191B45864856

P356

Q34726309-3DE6B5C5-7DD3-4690-8C49-97FDCD4D4771

P433

Q34726309-0E137279-C02C-4D9D-8400-E2B04C1E8E36

P478

Q34726309-A713A89C-E3A3-4F1A-B27E-89EE9E8DA650

P577

Q34726309-9CC8EB1E-CFF5-4F30-A9F4-6184DE0942E3

P5875

Q34726309-39219D55-9482-43E1-9FAC-2797C7F66B98

P6179

Q34726309-38C81D2E-A9A5-448D-B2C2-19FEA8782EBD

P698

Q34726309-FE0AA759-A551-4058-B79B-41BC5DD02EC0

P921

Q34726309-B1EE4496-1F00-4309-B310-1086C878F2F8

P932

Q34726309-1C962331-237B-48E8-A39D-DF9208C40E52

P356

S13300-014-0073-Z

P1433

Diabetes Therapy

P1476

The clinical development progr ...... ke Peptide-1 receptor agonist.

@en

P2093

Stephen C Bain

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Incretin-based therapies for type 2 diabetes mellitus.

P2888

s13300-014-0073-z

P304

367-383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-014-0073-Z

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263972071

http://www.w3.org/2001/XMLSchema#string

P6179

1035046360

http://www.w3.org/2001/XMLSchema#string

P698

25027491

http://www.w3.org/2001/XMLSchema#string

P921

P932

4269639

http://www.w3.org/2001/XMLSchema#string